These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 20809360)
1. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts. Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360 [TBL] [Abstract][Full Text] [Related]
2. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor. Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286 [TBL] [Abstract][Full Text] [Related]
3. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Long BJ; Jelovac D; Thiantanawat A; Brodie AM Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443 [TBL] [Abstract][Full Text] [Related]
4. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Belosay A; Brodie AM; Njar VC Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540 [TBL] [Abstract][Full Text] [Related]
7. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373 [TBL] [Abstract][Full Text] [Related]
8. [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. Fukushima M Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968 [TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitors in human lung cancer therapy. Weinberg OK; Marquez-Garban DC; Fishbein MC; Goodglick L; Garban HJ; Dubinett SM; Pietras RJ Cancer Res; 2005 Dec; 65(24):11287-91. PubMed ID: 16357134 [TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors and breast cancer. Macedo LF; Sabnis G; Brodie A Ann N Y Acad Sci; 2009 Feb; 1155():162-73. PubMed ID: 19250202 [TBL] [Abstract][Full Text] [Related]
12. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. Sonne-Hansen K; Lykkesfeldt AE J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667 [TBL] [Abstract][Full Text] [Related]
14. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180 [TBL] [Abstract][Full Text] [Related]
15. Aromatase and breast cancer. Brodie A; Sabnis G; Jelovac D J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. Nair HB; Kirma NB; Ganapathy M; Vadlamudi RK; Tekmal RR Steroids; 2011 Jul; 76(8):792-6. PubMed ID: 21477609 [TBL] [Abstract][Full Text] [Related]
17. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175 [TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice. Haga S; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Fukushima M; Kajiwara T Anticancer Res; 1999; 19(3A):1791-6. PubMed ID: 10470117 [TBL] [Abstract][Full Text] [Related]
19. P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells. Li HJ; Wang LY; Qu HN; Yu LH; Burnstock G; Ni X; Xu M; Ma B Mol Cell Endocrinol; 2011 May; 338(1-2):28-37. PubMed ID: 21356271 [TBL] [Abstract][Full Text] [Related]
20. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Han GZ; Liu ZJ; Shimoi K; Zhu BT Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]